



## **Management Team**

Alphamerix has a strong management team, with considerable experience in building companies and creating value. The team has a broad range of expertise that spans scientific, commercial and financial disciplines. The company has Dr Clive Rankin, formerly of Laporte plc and Degussa AG, as its Chairman.

### **Dr Stephen Mann, Chief Executive Officer and Business Development Director**

Stephen Mann, a co-founder of Alphamerix, has over 30 years experience in fundamental enzymology and enzyme catalysis. Working at the Babraham Institute he worked in enzymology related to neurochemistry and pharmacology. He has a wide experience of catalysis and experience of molecular biology, especially the expression of cloned enzyme genes. He joined Enzymatix on secondment and went on to become Business Development Manager for speciality enzymes and microbial products. This was a business he successfully transferred to Biotal where he was Technical Director for 5 years. On returning to Cambridge he concentrated on developing the technical commercial and supply aspects of enzyme catalysis with Mann Associates, his consulting company, from which much of the commercial activities of Alphamerix derive. As CEO he also deals with business development as well as corporate and strategic issues.

### **Dr Steve Taylor, Research Director**

Steve Taylor, a co-founder of Alphamerix, has 18 years of experience in industrial and academic biocatalysis. He joined Enzymatix Ltd. in 1989 following a PhD in whole-cell oxidative biotransformations at Imperial College. As Enzymatix evolved into Chiroscience he set up a skilled biotransformations team and chiral analysis group, who discovered and developed a number of enzymes that went on to be applied commercially at large scale. Later, in Chirotech Technology Ltd., then Ascot and more recently The Dow Chemical Company, he was Head of Biocatalysis, applying biocatalysis for many customer products. In addition, he has developed the application of enzymes for the synthesis of new advanced chiral building blocks, applying these in turn for the synthesis of new bioactive molecules. He has published extensively in the literature, and is inventor of several patents. Steve Taylor is now Research Director for Alphamerix.

## **Scientific Advisory Panel**

Alphamerix values very highly the advice and opinions of people who are experts in their scientific field. To assist us in our science and technology programs we have appointed Professor Stan Roberts, Professor Jenny Littlechild and Professor Stewart Gilmour to help us in the capacity of scientific advisors, with Professor Roberts as Chairman of this panel. All are internationally recognised scientists, who bring a wealth of experience in

medicinal chemistry, catalysis, biotransformations, protein structure and biochemistry in relation to disease.

**Professor Stanley M Roberts:**

**Professor of Organic Chemistry, University of Liverpool**

Professor Roberts began his academic career at the University of Salford before joining Glaxo (now GSK) as Head of Chemistry. After leaving Glaxo, Stan accepted a chair at the University of Exeter and developed a unique and highly successful group combining chemistry, biochemistry and enzyme technology in chemical synthesis. He joined Liverpool in 1995 to further develop this work and expand his activities in medicinal chemistry and biocatalytic systems, during which time he co-founded Stylacats. He is currently involved in setting up the UK Centre of Excellence for Biocatalysis, Bioprocessing and Biomanufacturing.

**Professor Jenny A Littlechild:**

**Professor of Biological Chemistry, University of Exeter**

Professor Littlechild started her academic career at Princeton University before moving on to the Max-Planck Institute. After returning to the UK to Bristol University, she joined the University of Exeter in 1991 connecting the disciplines of biochemistry, bioinformatics and chemistry, where she progressed to become Professor of Biological Chemistry in 1999. Jenny is internationally recognised for her work on the structure of important enzymes implicated in disease processes, and towards enzymes used in biocatalysis, especially from extremophiles. Following a successful bid to the Wellcome Trust, she is currently also Director for the Henry Wellcome Centre for Biocatalysis at Exeter, a new multi-million pound building dedicated to the study of biocatalysis and its applications in pharmaceutical and industrial chemistry, and in medicine and bioinformatics.

**Professor Stewart Gilmour:**

**Professor of Biomedical Science, University of Auckland**

Professor Gilmour is a biochemist of international reputation, who began his career in 1967 at the Beatson Institute of Cancer Research in Glasgow, where he was the Group Head from 1972-1984. Following this, he was the Head of the Department of Biochemistry at the Babraham Institute in Cambridge, pioneering work in the regulation of insulin-like growth factor gene expression. In 1996 he moved to New Zealand, where Stewart led a group focussing on cellular signalling and the involvement of insulin-like growth factor, as Deputy Director of the Liggins Institute and Professor of Biomedical Science within the Faculty of Medicine and Health Sciences at Auckland University. He is

currently also Chief Scientific Officer of Endocrinz Ltd. (now Neuren Pharmaceuticals), a biotech company in New Zealand that specialises in neurological and metabolic diseases. He has published widely in the biomedical literature with over 150 papers.